Skip to Content
Is your RA under control? Take an assessment and find out

Orencia (abatacept) Disease Interactions

There are 5 disease interactions with Orencia (abatacept):

Major

Abatacept (Includes Orencia) ↔ Hepatitis B

Severe Potential Hazard, Moderate plausibility

Applies to: Infectious Hepatitis

Abatacept, as other antirheumatic therapies have been associated with hepatitis B reactivation. Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with abatacept. Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.

Major

Abatacept (Includes Orencia) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Sepsis, Infection - Bacterial/Fungal/Protozoal/Viral

There have been reports of serious infections, including sepsis and pneumonia in patients receiving abatacept. Caution and close monitoring is recommended when considering the use of abatacept in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections. Administration of abatacept should be discontinued if a patient develops a serious infection.

Moderate

Abatacept (Includes Orencia) ↔ Copd

Moderate Potential Hazard, Moderate plausibility

Applies to: Chronic Obstructive Pulmonary Disease

In studies, patients with chronic obstructive pulmonary disease (COPD) treated with abatacept developed adverse events more frequently than those treated with placebo, including COPD exacerbations, cough, rhonchi, dyspnea and pneumonia. Caution should be exercised in patients with RA and COPD being treated with abatacept such patients should be monitored for worsening of their respiratory status.

Moderate

Abatacept (Includes Orencia) ↔ Diabetes

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Caution should be taken when prescribing abatacept for intravenous administration to diabetic patients as the intravenous formulation of abatacept contains maltose which can give falsely elevated blood glucose readings with certain blood glucose monitors on the day of abatacept infusion. If a patient is using such a monitor, advise the patient to discuss with their healthcare professional methods that do not react with maltose, such as using a different way to monitor your blood sugar levels.

Moderate

Abatacept (Includes Orencia) ↔ Tuberculosis

Moderate Potential Hazard, Moderate plausibility

Applies to: Tuberculosis -- Latent, Tuberculosis -- Active

Prior to initiating abatacept, patients should be screened for latent tuberculosis infection with a tuberculin skin test. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with abatacept. Caution should be taken when prescribing abatacept to these patients as this agent has not been studied in patients with a positive tuberculosis screen, and the safety of abatacept in individuals with latent tuberculosis infection is unknown. Anti-tuberculosis therapy should also be considered prior to initiation of abatacept in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Tuberculosis should be strongly considered in patients who develop a new infection during abatacept treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

Orencia (abatacept) drug Interactions

There are 108 drug interactions with Orencia (abatacept)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide